FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130409480> ?p ?o ?g. }

• W3130409480 endingPage "06" @default.
• W3130409480 startingPage "PS14" @default.
• W3130409480 abstract "Abstract Background: The global COVID-19 pandemic has placed unprecedented burden on individual oncology patients, oncology departments, hospitals and national health systems. In order to protect individual patients from the risk of COVID-19 infection as well as improve capacity for COVID-19 patient management, a series of national and internationally agreed measures were proposed. During the first wave of infections the virulence and effect on cancer patients was not known. It is vitally important that the measures implemented to combat these risks are assessed and evaluated in order to learn best how to manage potential future waves of known and unknown viral infections.Methods: The international ESMO COVID-19 guidelines and national (NICE) guidelines were implemented across Kent, UK. All changes to treatment regimens were audited to assess what were the most frequent changes and in which patient groups could these be implemented. Data was subdivided for both early and advanced breast cancer as well as ER+, HER2+ or triple negative disease.Results: We collected full treatment history from 1,718 breast cancer patients currently receiving active oncology treatments. We were able to change treatment regimens due to COVID19 for 32.8% of patients. Of these 27.1% were early breast cancer patients compared with 43.7% were those with advanced metastatic disease. The most common changes for neoadjuvant changes were proceeding to surgery before completion of planned chemotherapy (10.2%), switch to 3 weekly Paclitaxel (10%) and chemotherapy break (8%). For adjuvant patients the most common changes included postponement of bisphosphonates (70.8%), chemotherapy break (13.5%), and curtailment to 6 months of adjuvant Trastuzumab (10.4%). For our palliative patients the most common changes included delay CDK4/6 inhibitor treatment (79.2%), postponement of bisphosphonates (24.8%), break in HER2 antibody (9.6%) and break in chemotherapy (8%).Conclusions: A large proportion of breast cancer oncology patients were deemed suitable to have a change in original planned treatment. We are fortunate to have comparatively large number of treatment options that can be customised on a patient basis to individual reduce risk of COVID-19. Further analysis is needed over time to compare the oncological outcomes of those in whom treatment was changes from the current gold standards of care. Citation Format: Simon N Rodney, Charlotte Abson, Russell Burcombe, Rema Jyothirmayi, Catherine Harper-Wynne. Changes in management of breast cancer patients during first wave of COVID19, throughout the area of Kent, United Kingdom. An audit of ESMO guideline implementation [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-06." @default.
• W3130409480 created "2021-03-01" @default.
• W3130409480 creator A5007948659 @default.
• W3130409480 creator A5009168570 @default.
• W3130409480 creator A5016184299 @default.
• W3130409480 creator A5016209096 @default.
• W3130409480 creator A5045382346 @default.
• W3130409480 date "2021-02-15" @default.
• W3130409480 modified "2023-09-30" @default.
• W3130409480 title "Abstract PS14-06: Changes in management of breast cancer patients during first wave of COVID19, throughout the area of Kent, United Kingdom. An audit of ESMO guideline implementation" @default.
• W3130409480 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-06" @default.
• W3130409480 hasPublicationYear "2021" @default.
• W3130409480 type Work @default.
• W3130409480 sameAs 3130409480 @default.
• W3130409480 citedByCount "1" @default.
• W3130409480 countsByYear W31304094802022 @default.
• W3130409480 crossrefType "journal-article" @default.
• W3130409480 hasAuthorship W3130409480A5007948659 @default.
• W3130409480 hasAuthorship W3130409480A5009168570 @default.
• W3130409480 hasAuthorship W3130409480A5016184299 @default.
• W3130409480 hasAuthorship W3130409480A5016209096 @default.
• W3130409480 hasAuthorship W3130409480A5045382346 @default.
• W3130409480 hasConcept C121608353 @default.
• W3130409480 hasConcept C126322002 @default.
• W3130409480 hasConcept C142724271 @default.
• W3130409480 hasConcept C143998085 @default.
• W3130409480 hasConcept C162324750 @default.
• W3130409480 hasConcept C177713679 @default.
• W3130409480 hasConcept C187736073 @default.
• W3130409480 hasConcept C199360897 @default.
• W3130409480 hasConcept C199521495 @default.
• W3130409480 hasConcept C2776694085 @default.
• W3130409480 hasConcept C2779134260 @default.
• W3130409480 hasConcept C2779256446 @default.
• W3130409480 hasConcept C2780182762 @default.
• W3130409480 hasConcept C3008058167 @default.
• W3130409480 hasConcept C41008148 @default.
• W3130409480 hasConcept C524204448 @default.
• W3130409480 hasConcept C530470458 @default.
• W3130409480 hasConcept C71924100 @default.
• W3130409480 hasConcept C89623803 @default.
• W3130409480 hasConceptScore W3130409480C121608353 @default.
• W3130409480 hasConceptScore W3130409480C126322002 @default.
• W3130409480 hasConceptScore W3130409480C142724271 @default.
• W3130409480 hasConceptScore W3130409480C143998085 @default.
• W3130409480 hasConceptScore W3130409480C162324750 @default.
• W3130409480 hasConceptScore W3130409480C177713679 @default.
• W3130409480 hasConceptScore W3130409480C187736073 @default.
• W3130409480 hasConceptScore W3130409480C199360897 @default.
• W3130409480 hasConceptScore W3130409480C199521495 @default.
• W3130409480 hasConceptScore W3130409480C2776694085 @default.
• W3130409480 hasConceptScore W3130409480C2779134260 @default.
• W3130409480 hasConceptScore W3130409480C2779256446 @default.
• W3130409480 hasConceptScore W3130409480C2780182762 @default.
• W3130409480 hasConceptScore W3130409480C3008058167 @default.
• W3130409480 hasConceptScore W3130409480C41008148 @default.
• W3130409480 hasConceptScore W3130409480C524204448 @default.
• W3130409480 hasConceptScore W3130409480C530470458 @default.
• W3130409480 hasConceptScore W3130409480C71924100 @default.
• W3130409480 hasConceptScore W3130409480C89623803 @default.
• W3130409480 hasIssue "4_Supplement" @default.
• W3130409480 hasLocation W31304094801 @default.
• W3130409480 hasOpenAccess W3130409480 @default.
• W3130409480 hasPrimaryLocation W31304094801 @default.
• W3130409480 hasRelatedWork W2321725762 @default.
• W3130409480 hasRelatedWork W2348231456 @default.
• W3130409480 hasRelatedWork W2354050160 @default.
• W3130409480 hasRelatedWork W2367105124 @default.
• W3130409480 hasRelatedWork W2368979736 @default.
• W3130409480 hasRelatedWork W2369039771 @default.
• W3130409480 hasRelatedWork W2379151083 @default.
• W3130409480 hasRelatedWork W2388730008 @default.
• W3130409480 hasRelatedWork W2782589310 @default.
• W3130409480 hasRelatedWork W2791179561 @default.
• W3130409480 hasVolume "81" @default.
• W3130409480 isParatext "false" @default.
• W3130409480 isRetracted "false" @default.
• W3130409480 magId "3130409480" @default.
• W3130409480 workType "article" @default.